Cannabis should be rescheduled within the Misuse of Drugs Act to allow research to take place, say the vast majority of respondents to a Royal Pharmaceutical Society (RPS) survey.
Cannabis and cannabis-derived products are currently listed under Schedule 1 of the Act, meaning they are considered to have no known medicinal value and cannot legally be purchased or prescribed for medicinal use. Moving cannabis to Schedule 2 would allow for licensed cannabis-based medicines to be prescribed and possessed lawfully by patients with a prescription. It would also enable research into the medicinal properties of cannabis, potentially leading to new cannabis-derived medicinal products.
The RPS carried out a survey and asked pharmacists whether they believed that cannabis should